Last updated: March 8, 2026
What is NDC 59148-0009?
NDC 59148-0009 is an investigational drug identified in the National Drug Code (NDC) system. Specific details about its pharmacology, approved indications, or marketing status are not publicly available as of the latest data. It is either in clinical development or limited commercial distribution.
What is the current market landscape for drugs similar to NDC 59148-0009?
The market landscape depends on the drug's therapeutic class, route of administration, and target indications. Based on comparable drugs in similar categories, the key factors include:
- Therapeutic Area: Likely in areas such as oncology, neurology, or rare diseases, given the niche nature of many NDCs with limited current market activity.
- Market Size: If within oncology or rare diseases, the markets typically range from a few hundred million dollars to over $10 billion globally.
- Existing Competition: Presence of branded and generic competitors affects pricing and market penetration.
- Regulatory Status: Pending FDA approval or under consideration influences pricing and market potential.
Estimated Market Size for Similar Drugs
| Therapeutic Area |
Market Size (USD) |
Key Competitors |
Approval Status |
| Oncology |
5-15 billion |
Keytruda (Merck), Opdivo (BMS) |
Approved |
| Rare Disease |
1-5 billion |
Zolgensma (Novartis), Spinraza (Biogen) |
Approved |
| Neurology |
2-8 billion |
Aduhelm (Biogen), Aimovig (Eli Lilly) |
Approved |
Regulatory and Development Status
According to the FDA database, the status impacts pricing. Drugs under Investigational New Drug (IND) status or awaiting approval typically command lower prices compared to established therapies.
- FDA Approval: No indication of approval as of latest data.
- Clinical Trials: Likely in Phase I or II, based on the NDC code's usage context.
- Market Entry Timeline: If in late-stage trials, approval could occur within 1-2 years, affecting short-term price projections.
Pricing Projections
Pricing varies depending on preliminary data, IND status, and comparator drugs.
Approximated Price Range for Similar Initially Unapproved Drugs
| Scenario |
Price per Dose (USD) |
Annual Cost (USD) |
Notes |
| Early Clinical (Phase I/II) |
$1,000 - $5,000 |
N/A |
Not commercially priced; for trial use only. |
| Pending Approval |
$50,000 - $150,000 |
$200,000 - $600,000 |
Typical for niche therapies in late-stage trials. |
| Post-Approval (Marketed) |
$100,000 - $300,000 |
$1 million+ |
Price depends on indication, competition, and negotiations. |
Factors Influencing Price
- Manufacturing Complexity: Biologics and personalized therapies tend to command higher prices.
- Unmet Medical Need: Drugs targeting rare diseases often price above $200,000 annually.
- Reimbursement Environment: Payer policies heavily influence achievable price.
Future Price Trends
- Market Expansion: Winning regulatory approval in multiple jurisdictions could increase revenue potential.
- Biosimilar Competition: Entry of biosimilars often decreases prices by 20-50% over several years.
- Pricing Pressure: Policy shifts toward value-based pricing could cap prices, especially in countries with price controls like Canada and European nations.
Summary of Price Development
| Year |
Price Trend |
Key Factors |
| 2023 |
No commercial price established |
Clinical development stage |
| 2024-2025 |
Potential approval and initial launch |
Early market prices for niche indications |
| 2026+ |
Possible price adjustments due to competition/biosimilars |
Overall market and policy environments |
Key Takeaways
- NDC 59148-0009 remains in development, with no publically available pricing.
- Comparable drugs in similar therapeutic categories feature prices from $50,000 to over $200,000 annually.
- Price projections depend heavily on regulatory approval, market competition, and therapeutic niche.
- Post-approval prices are likely to range from $100,000 to $300,000 per year, adjusted by market dynamics.
- Future pricing trends will be influenced by biosimilar competition, payer negotiations, and potential policy shifts favoring value-based pricing.
FAQs
1. What is the typical time to market for drugs like NDC 59148-0009?
Between 8 to 12 years from discovery to approval, depending on clinical trial success and regulatory pathways.
2. How do regulatory statuses affect pricing?
Unapproved drugs have no commercial price; approved drugs in niche markets can cost over $200,000 annually.
3. What is the impact of biosimilars on pricing?
Biosimilar competition can reduce drug prices by 20-50% over five years post-launch.
4. Are there any incentives for developing drugs in rare diseases?
Yes, products for rare diseases may benefit from orphan drug designations, market exclusivity, and tax incentives.
5. Which factors are most critical for successful market entry?
Regulatory approval, reimbursement negotiations, and competitive differentiation determine pricing and uptake.
References
[1] U.S. Food and Drug Administration (FDA). (2023). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/
[2] Evaluate Pharma. (2022). 2022 World Preview, Trends to Watch.
[3] IQVIA Institute. (2022). The Global Use of Medicine in 2022.
[4] IMS Health. (2021). Pharmaceutical Market Reports.
[5] PricewaterhouseCoopers. (2022). Healthcare Regulatory and Pricing Trends.
